The crystal structure of the TolB box of colicin A in complex with TolB reveals important differences in the recruitment of the common TolB translocation portal used by group A colicins

Ying Zhang,^{1†} Chan Li,^{2†} Mireille N. Vankemmelbeke,¹ Philip Bardelang,¹ Max Paoli,^{2‡}

Christopher N. Penfold^{1*} **and Richard James**^{1**} ¹Institute of Infection, Immunity and Inflammation, School of Molecular Medical Sciences, and ²School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham NG7 2RD, UK.

Summary

Interaction of the ToIB box of Group A colicins with the ToIB protein in the periplasm of Escherichia coli cells promotes transport of the cytotoxic domain of the colicin across the cell envelope. The crystal structure of a complex between a 107-residue peptide (TA₁₋₁₀₇) of the translocation domain of colicin A (CoIA) and ToIB identified the ToIB box as a 12-residue peptide that folded into a distorted hairpin within a central canyon of the β-propeller domain of TolB. Comparison of this structure with that of the colicin E9 (ColE9) TolB box-ToIB complex, together with site-directed mutagenesis of the CoIA ToIB box residues, revealed important differences in the interaction of the two ToIB boxes with an overlapping binding site on ToIB. Substitution of the ToIB box residues of CoIA with those of CoIE9 conferred the ability to competitively recruit ToIB from Pal but reduced the biological activity of the mutant CoIA. This datum explains (i) the difference in binding affinities of CoIA and CoIE9 with ToIB, and (ii) the inability of CoIA, unlike CoIE9, to competitively recruit ToIB from Pal, allowing an understanding of how these two colicins interact in a different way with a common translocation portal in E. coli cells.

Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.interscience.wiley.com/ authorresources/onlineopen.html

© 2009 The Authors Journal compilation © 2009 Blackwell Publishing Ltd

Introduction

Many proteins of eubacterial or of eucaryotic origin contain stretches of > 30 amino acids that are natively (intrinsically) disordered regions (NDRs) (Ward et al., 2004). Native disorder occurs in regions with a high glycine content and a prevalence of charged or polar residues that preclude the formation of a hydrophobic core or stable three-dimensional fold. Such NDRs are important in many biological processes such as transcription, translation, intracellular signalling and hostpathogen interactions where their roles are to bind to other macromolecules to form complexes (Dyson and Wright, 2005). NDRs undergo disorder-order transitions on binding a partner molecule (Wright and Dyson, 1999). Coupling a folding transition to a protein-protein interaction may be functionally advantageous as it could contribute to the specificity of the molecular recognition, enhance the rate of the interaction, allow binding of one protein to several different target molecules, and could provide for large intermolecular interfaces within a relatively small protein (Gunasekaran et al., 2003). Recent studies with colicins have highlighted the important role of NDRs in the complex protein-protein interactions that drive cellular uptake of these proteins (Collins et al., 2002; Macdonald et al., 2004; Tozawa et al., 2005).

Colicins are plasmid-encoded, protein antibiotics that consist of three domains; an N-terminal translocation (T) domain, a central receptor-binding (R) domain and a C-terminal cytotoxic domain (James *et al.*, 2002). The mechanism of cell killing by colicins is either by forming pores in the cytoplasmic membrane (e.g. colicins A, B, E1 or N) (Elkins *et al.*, 1997); a non-specific DNase that belongs to the H-N-H family of homing endonucleases (colicin E2, E7, E8 and E9) and shows homology to DNases responsible for eucaryotic apoptosis (Walker *et al.*, 2002); a 16S RNase (colicins E3, E4, E6 and cloacin DF13) (Boon, 1971; Senior and Holland, 1971); or an anticodon tRNase (colicin E5) (Ogawa *et al.*, 1999). Colicin E2-E9 producing strains protect themselves against killing by producing a plasmid-encoded, immunity

Accepted 14 July, 2009. For correspondence. *E-mail chris.penfold@ nottingham.ac.uk; Tel. (+44) 115 8467957; Fax (+44) 115 8468002; **E-mail: richard.james@nottingham.ac.uk; Tel. (+44) 115 8467952; Fax (+44) 115 8467951. [†]These two authors contributed equally to the work. [‡]Current contact: max_paoli@yahoo.com

protein that forms a complex with its cognate cytotoxic domain on synthesis, for example CoIE9/Im9 (Kleanthous *et al.*, 1999). To facilitate import of their cytotoxic domains to their cellular site of action, group A colicins, such as the E colicins and colicin A (CoIA), use the *tol*-dependent translocation system that consists of the ToIQ, ToIR, ToIA, ToIB and Pal proteins, and constitutes a transmembrane protein translocation portal or translocon (James *et al.*, 1996; Zakharov *et al.*, 2004).

The normal cellular function of the tol system in Escherichia coli is uncertain. It appears to play a role in maintaining the integrity of the cell envelope, transducing energy from the cytoplasmic membrane, and may form a dynamic subcomplex at constriction sites to promote the energydependent septal wall formation across invaginating peptidoglycan and inner membrane layers during cell division (Cascales et al., 2001; Goemaere et al., 2007; Gerding et al., 2007). TolB is a periplasmic protein, whose crystal structure was independently determined by two groups (Abergel et al., 1999; Carr et al., 2000), and is associated with the outer membrane via an interaction of its C-terminal β-propeller domain with the peptidoglycanassociated lipoprotein (Pal) (Bouveret et al., 1995), and with ToIA via its N-terminal domain (Dubuisson et al., 2002). The ToIB protein is essential for mouse-lethal infection by Salmonella typhimurium (Bowe et al., 1998). TolA is a 44 kDa periplasmic protein that is anchored in the cytoplasmic membrane via a single transmembrane region (ToIAI) that is important for interactions with the ToIQ and ToIR proteins in the membrane (Germon et al., 2001). TolQ and TolR are transmembrane proteins that are involved in the pmf-dependent activation of ToIA (Cascales et al., 2001) which shuttles energy from the inner to outer membrane through its association with Pal anchored to the outer membrane (Lloubès et al., 2001; Cascales et al., 2002). ToIA spans the periplasm via its extended central domain (ToIAII), and binds to both ToIB (Dubuisson et al., 2002; Walburger et al., 2002) and Pal (Cascales et al., 2000) via its C-terminal domain (TolAIII). TolA has recently been shown to be important in the energy dependent loss of immunity protein from the ColE9/Im9 complex possibly through its interaction with ToIB (Vankemmelbeke et al., 2009).

All the information required for translocation of colicins is found in their T domains. ColA interacts with TolB through a TolB box (DGTGW), that has been localized to residues 11–15 in the T domain of ColA (Bouveret *et al.*, 1997) and shares high sequence homology with part of the TolB box of other group A colicins such as ColE9 (DGSGW) (Garinot-Schneider *et al.*, 1997). The TolB box of ColE9 was later shown to be extended to include 15 contiguous residues with a tryptophan at residue 46 which is essential for anchoring the TolB box into the TolB canyon on the surface of the β -propeller domain (Hands *et al.*, 2005; Loftus *et al.*, 2006). The N-terminal translocation domain of CoIE9 is natively disordered but contains clusters of interacting side-chains, one of which is centred around the ToIB box residues 35–39 (DGSGW) (Collins *et al.*, 2002; Macdonald *et al.*, 2004; Tozawa *et al.*, 2005). The Predictors of Natural Disordered Regions (PONDR[®]) programme (Romero *et al.*, 1997) has predicted a high percentage of disorder over the first 150 residues of the T domain of CoIA, particularly around the ToIB box.

Both CoIE9 and CoIA bind to the BtuB outer membrane receptor and OmpF co-receptor and then recruit ToIB, via their ToIB boxes, during translocation, but they differ in their interactions with ToIA. CoIA recruits ToIA during translocation (Bénédetti *et al.*, 1991), whereas no physiological interaction has ever been demonstrated in yeast two hybrid, surface plasmon resonance (SPR) or isothermal titration calorimetry experiments between CoIE9 and ToIA. However, as an *E. coli toIA* mutant is resistant to killing by CoIE9, the ToIA protein must be required, possibly indirectly through its interaction with ToIB, for the translocation of CoIE9.

In this paper we have used site-directed mutagenesis data together with the elucidation of the corrystal structure of a ToIB box containing peptide consisting of the N-terminal 107 residues of CoIA (TA₁₋₁₀₇) bound to ToIB to show that the ToIB box of CoIA consists of a 12-residue domain that binds to the β -propeller canyon of ToIB. Comparison with the published cocrystal structure of a synthetic ToIB box peptide of CoIE9 bound to ToIB (Loftus *et al.*, 2006) indicates differences in the intermolecular binding patterns of both colicins to an overlapping binding pocket that helps to explain the observed differences in the affinity of binding and recruitment mechanisms of these two colicins for ToIB. This datum is discussed in the context of a model for the translocation of these two colicins.

Results

Prediction of the TolB boxes of group A colicins

The ToIB box in CoIE9 consists of 15 contiguous residues with the sequence 32-GASDGSGWSSENNPW-46 (Hands *et al.*, 2005) (Fig. 1). Using deletion analysis, the ToIB box of CoIA was predicted to include residues 7–20 (Bouveret *et al.*, 1998; Journet *et al.*, 2001). Sequence alignment of the *tol*-dependent colicins showed that the DG(S/T)GWSSE residues are highly conserved in all of the enzymatic and pore-forming colicins (shown in bold in Fig. 1). Previous mutagenesis studies have shown that the G38 residue of CoIE9 is not essential for activity (Garinot-Schneider *et al.*, 1997), and that the S37 residue of CoIE9 can be substituted by threonine without significant loss of function (Hands *et al.*, 2005). We therefore

Pore-forming colicins

- 7 GGKGDGTGWSSERGSGPEPGGGSHG 31 ColA
- 7 GGHGDGTGWSSERGDGPAPGGGMQG 31 ColU
- 7 GGYGDGTGWSSESG GPAPGGGMHG 30 ColY
- 7 GGKG**DGT**N**WSSE**RGTGPEPGGGDKG 31 Col28b
- 15 GGKGDGTSWSSERGSEPAPGGGSHG 39 Klebicin D

Enzymatic colicins

- 31 GGASDGSGWSSENNPWGGGSGSIHW 55 ColE9
- 31 GGASDGSGWSSENNPWGGGSGSIHW 55 ColE7
- 31 GGASDGSGWSSENNPWGGGSGSGIH 55 ColE6
- 31 GGASDGSGWSSENNPWGGGSGSIHW 55 ColE3
- 31 GGASDGSGWSSENNPWGGGSGSIHW 55 ColE2
- 32 GGASDNSGWSSENNPWGGGNSGMIG 56 Alveicin A

Fig. 1. Alignment of residues of the TolB box region of pore-forming and enzymatic group A colicins. Residues of the extended TolB box of ColE9 and residues of the TolB box sequence that are conserved in the other colicin sequences are shown in bold. The residue numbers are indicated at the start and end of each sequence. A padding space has been introduced in the ColY sequence to optimize the alignment. Colicins A, U, Y and E2-E9 are produced by *E. coli*, Col28b is produced by *Serratia marcescens*, Klebicin D is from *Erwinia tasmaniensis* and Alveicin A is from *Hafnia alvei*.



assume that substitution of G14 of ColA to N14 or S14 of Col28b and Klebicin D respectively, and G36 of ColE9 to N34 of Alveicin A would similarly not affect biological activity. It is intriguing that ColA and the other pore-forming colicins are missing the last four residues of the extended TolB box of ColE9 (43-NNPW-46) which are replaced by RGSG in ColA. We have previously demonstrated that the N44A and W46A mutations resulted in loss of biological activity of ColE9, with the latter mutation abolishing the interaction with TolB (Hands *et al.*, 2005).

Mutagenesis of the TolB box of ColA

Alanine scanning mutagenesis was conducted across the region from residue K9 to P25 to determine the extent of the ToIB box of CoIA and the contribution of individual residues to the binding of ToIB. The biological activity of the alanine mutants in comparison with CoIA (Fig. 2A) indicates that mutations in residues D11, T13, W15 or E18 abolished the biological activity of the mutant colicin. In contrast, alanine mutations of residues G12, G14, R19, G20 or G22 had little effect on biological activity while alanine mutations of residues S17 and S21 had no effect, and thus also presumably contribute little to the affinity of binding to ToIB. We are, however, aware that the N44A

Fig. 2. Alanine scanning mutagenesis of residues of the ToIB box of CoIA. A. Individual alanine mutations were engineered into CoIA from Lys9 to Pro25 and their effect on the activity of CoIA was determined using the spot test assay using doubling dilutions of purified proteins from 25 nM to 0.1 nM.

B. The effect of each ToIB box mutant of TA_{1-107} on the TA_{1-107} -ToIB interaction was determined by surface plasmon resonance and expressed in response units (RU) in the presence (grey bars) and absence (black bars) of 1 mM Ca²⁺.

TolB recruitment by colicin A 625

^{© 2009} The Authors Journal compilation © 2009 Blackwell Publishing Ltd, *Molecular Microbiology*, **75**, 623–636

626 Y. Zhang et al.

mutation in the ToIB box of CoIE9 that abolished biological activity did not affect binding of the mutant colicin to ToIB (Hands et al., 2005). Consequently, we determined the interaction of the CoIA ToIB box containing peptide (TA1-107) and all the TA₁₋₁₀₇ alanine mutants, from K9 to P25 with ToIB by SPR, in the presence or absence of Ca²⁺ (Fig. 2B), as Ca²⁺ has been shown previously to dramatically increase the binding affinity of the CoIE9 ToIB box for ToIB (Loftus et al., 2006). Corrected sensorgrams and residual plots for the interaction of ToIB with CoIA and ColA E18A are shown in Fig. S1. In the presence of Ca²⁺ the affinity of binding (K_d) of TA₁₋₁₀₇ to ToIB was 1.6 μ M, compared with a value of 24.3 μ M in the absence of Ca²⁺. indicating a similar enhancement by Ca2+ of the binding of CoIA to ToIB. Compared with TA₁₋₁₀₇, alanine substitutions of residues K9 and S21 to P25 did not affect binding to ToIB, whereas alanine substitutions of all residues between G10 and G20, with the exception of G14, resulted in either complete inhibition or significantly reduced binding to ToIB when compared with that of CoIA (Fig. 2). Interestingly, the ColA S16A mutant had partial biological activity using the spot test assay but a binding affinity to ToIB that was very weak and similar to the inactive mutants, D11A, T13A, W15A and E18A. As the spot test assay only measures the activity of a colicin at the end of a 16 h incubation period, it is possible that this endpoint assay does not always fully differentiate between complexes that have different affinities or stabilities. Indeed, analysis of the biological activity of ColA containing the S16A mutation using a liquid growth assay over an 8 h period showed that the S16A mutation reduced the activity of CoIA by, at least, 1000-fold compared with CoIA, thus confirming the SPR data (Fig. S2). This datum indicates that the ToIB box of CoIA is located between residues G10 and G20 with many of the core residues being highly conserved between the toldependent enzymatic and pore-forming colicins (Fig. 1).

Crystal structure of the TA₁₋₁₀₇-TolB complex

CoIE9 binds to ToIB with an affinity of approximately 1 μ M or 90 nM in the presence of Ca²⁺ (Hands *et al.*, 2005; Loftus *et al.*, 2006). Comparison with data on the interaction of ToIB with the ToIB box of CoIA suggests an approximate 15–25-fold difference in affinities. In order to explain this difference, the structure of the complex of TA₁₋₁₀₇ bound to ToIB was determined so that a detailed comparison with the published structure of the ToIB box of CoIE9 in complex with ToIB could be established. We rectify an error in previous reports of the amino acid sequence of ToIB (PDB entry 1C5K) that include an additional incorrectly assigned methionine residue at the N-terminus.

The structure was refined to 2.6 Å resolution (see Table 1); and the model has excellent geometry with no

Table 1. X ray data collection and crystallographic refinement statistics for the TA_{1-107} -ToIB complex.

Data collection	
Wavelength (Å)	1.542
Space group	P1 2 ₁ 1
Resolution range (Å)	30-2.6 (2.67-2.6)
Unit cell parameters	a = 61.96, b = 40.17, c = 80.87,
	$\alpha = \gamma 90^\circ, \ \beta = 97.18^\circ$
No. of unique reflections	12220
Total no. of observations	44504
Redundancy	3.6 (3.7)
Mean I/o(I)	13.3 (3.7)
<i>l/</i> σ(l)	7.7 (2.2)
Completeness (%)	97.9 (96.6)
Rmerge (%)	9.5 (34.7)
Refinement	
Resolution range (Å)	30–2.6
R _{factor} (%)	19.3
R _{free} (%)	25.7
rmsd bond lengths (Å)	0.015
rmsd angles (°)	1.77
Average B-factor (protein, Å ²)	17
No. of protein atoms	3107
No. of water and ions atoms	70

Ramachandran outliers. The first electron density maps obtained with molecular replacement phases, using the known ToIB structure (1C5K), clearly revealed strong additional peaks of density at the side of the β -propeller fold located furthest away from the smaller α/β N-terminal domain of ToIB. Even though 107 amino acids of the translocation domain of CoIA were included in the crystal-lization, only residues 9–20 could be resolved in the electron density maps (Fig. 3A). No additional peaks of density were observed at any stage of the model building and refinement, therefore the remaining residues of the TA_{1–107} polypeptide are assumed to be disordered in the solvent channels within the crystal lattice.

The electron density was of sufficiently good quality to allow the placement of the colicin sequence with little ambiguity. However, in the absence of very highresolution data, we also refined, as tests, a structural model with the CoIA polypeptide fitted in the reverse order (Fig. S3). Difference maps and R_{free} statistics gave indisputable indications that this interpretation was incorrect. Our final colicin model fitted the density very well, with clean difference maps. ToIB, as previously described (Abergel et al., 1999; Carr et al., 2000), is composed of an α/β domain at the N terminus and a six-bladed β -propeller domain at the C terminus with a tunnel through the centre of the β -propeller. TA₁₋₁₀₇ binds within the larger of the cavities formed at the ends of the central tunnel of the TolB β -propeller domain (Fig. 3B), at the same location as the ColE9 TolB box peptide binds in the structure of the TE9pep32-47-ToIB complex (PDB entry 2IVZ) (Loftus et al., 2006). Refinement of two small, independent peaks of



Fig. 3. Structure of the TA_{1-107} -TolB complex.

A. Electron density map of residues 9–20 of TA₁₋₁₀₇ contoured at 0.95 σ . Residues 9–20 were the only ColA residues with any electron density in the TA₁₋₁₀₇–TolB cocrystal structure. Note, contouring was shown at 0.95 σ rather than 1 σ to provide a sharper representation of the electron density map given the resolution of the data.

B. Structure of the TA₁₋₁₀₇–ToIB complex at 2.6 Å resolution showing the colicin binding site of the β -propeller domain. Also visible are one Ca²⁺ ion (blue) in the central channel of the β -propeller domain and one Na⁺ ion (violet) between the β -propeller and N-terminal α/β -domains.

C. Intermolecular hydrogen bonding networks in the core region of the proximal half of the TA_{1-107} -ToIB peptide complex. CoIA residues are shown in blue and the ToIB residues are shown in green. The intermolecular hydrogen bonds are shown as black lines, three of which are mediated by water molecules.

positive density using water, monovalent and divalent cations suggested that one Ca²⁺ ion is present in the central channel of the β -propeller and a Na⁺ ion is present at the interface between the N-terminal α/β domain and β -propeller domain (Fig. 3B). The structure of ToIB in the complex is very similar to that of the free ToIB structure (1C5K), as demonstrated by the fact that the C^{α} atoms

superimpose with root-mean-square deviation (rmsd) of 0.54, indicating that TA_{1-107} binding to ToIB does not result in any major conformational change in ToIB; however, it should be borne in mind that the N-terminal residues 23–31 of ToIB are not visible in the free ToIB structure.

The molecular surface of the pocket in ToIB in contact with residues 9–20 of TA₁₋₁₀₇ is characterized by a mixture of hydrogen bonding donor and acceptors as well as hydrophobic patches (Tables S1 and S2). The intermolecular contacts are dominated by the interactions established by ColA residues that are essential for biological activity (Fig. 2). The first set of interactions are predominantly hydrophobic in nature, with only one hydrogen bond between W15 of ColA and D307 of TolB (Tables S1 and S2). Several non-polar contacts are also made by the W15 side-chain to residues P312, S306, T305, T291 of TolB, with additional interactions made by D11 and T13 with H245 and L268 of ToIB respectively (Table S2). The second cluster of interactions consist of mainly polar contacts, with E18 making three direct interactions and one water-mediated contact to ToIB, and S17 engaged in two further hydrogen bonds with ToIB, one direct and one water-mediated that bridges the Ca2+ ion deep in the binding pocket (Fig. 3C; Table S3). It can be argued that residues W15 and E18 are interaction hot spots for the TA₁₋₁₀₇-ToIB interface and are likely to provide a marked contribution to the energy of association. Both side-chains of T13 and W15 become buried in the complex, excluding a significant area of ToIB from the solvent and adding to the favourable energy provided by the total of 8 (5 direct) hydrogen bonding interactions that stabilize the association. All of the S17 and E18 interactions are buried into the binding pocket and appear to be virtually excluded from the bulk solvent, partly by the shielding from the side-chain of M203 of ToIB, which makes non-polar contacts with the aliphatic portion of the E18 residue (Table S2). Complex formation with TA1-107 results in the burial of 531 Å2 of the ToIB solvent accessible surface area which is less than the buried surface areas of ToIB in complex with Pal and TE9_{pep32-47} (Table S4). Hydrophobic residues in the TolB pocket such as M203, F219 and L268, which are relatively solvent exposed in the free ToIB molecule, become almost completely buried in the complex.

A total of eight direct (protein–protein) intramolecular hydrogen bonds exist in the structure of the ToIB binding epitope of TA_{1-107} that involve both main chain and side-chain atoms (Table S5). For example, S16 engages in four intramolecular interactions, two via its side-chain and two via its main chain. One of these, with D11, is a strong contact with a distance of 2.6 Å and good geometry. This contact is likely to contribute to stabilizing the conformation of the bound TA_{1-107} as both residues have a profound effect on the interaction with ToIB (Fig. 2). Nuclear magnetic resonance studies of the translocation domain of



Fig. 4. Comparison of TA₁₋₁₀₇-ToIB with TE9pep32-47-ToIB (PDB entry 2IVZ). A. Ball and stick comparison of the stereochemistry of the core region of the ToIB box of ColA (blue) with ColE9 (green). Intramolecular hydrogen bonds are shown in magenta dashed lines for CoIE9 and black dashed lines for CoIA. The hydrogen bond between S37 and S40 of TE9pep32-47-ToIB (shown by the arrow) has no equivalence in TA₁₋₁₀₇-ToIB due to the small perturbation in the position of the T13 residue. B. Ball and stick representation of residues 9–20 of TA_{1-107} bound to the central canyon of the ToIB β -propeller (left) in comparison with the TE9_{pep32-47}-ToIB interaction (right). The cyclizing hydrogen bond between G32 and N44 in ColE9 is shown as a green dashed line.

в



CoIE9 have shown the presence of clusters of interacting residues of the ToIB box that define a protein binding epitope which is subsequently weakened following the introduction of mutations to key residues within these clusters (Macdonald *et al.*, 2004; Tozawa *et al.*, 2005). Given the similarity of the core region of the ToIB boxes of CoIA and CoIE9, and the complex and extensive network of intramolecular hydrogen bonds it is reasonable to assume that, despite the lack of a well-defined secondary structural element in this segment of CoIA, part of the structure of this ToIB binding motif might be pre-formed in solution. It appears, in fact, that the intramolecular interactions could define and stabilize, even though temporarily, a productive conformation in terms of ToIB binding.

Comparison with the interactions in the ColE9–TolB complex

The structure of the complex of ToIB and the CoIE9derived peptide $TE9_{pep32-47}$ (2IVZ) demonstrated that the ToIB box in CoIE9 consists of a 15-residue peptide from 32-GASDGSGWSSENNPW-46 (Loftus *et al.*, 2006). Our structure of the complex of ToIB and TA_{1-107} has revealed that the ToIB box in CoIA is a 12-residue peptide with the sequence of 9-KGDGTGWSSERG-20. The ToIB boxes in CoIA and CoIE9 share a core sequence of DG(S/T)GWSSE, which superimpose well in the two structures except the G(S/T)G residues which are separated slightly away in the TA₁₋₁₀₇-ToIB structure (Fig. 4A). This results in the intramolecular hydrogen bond between S37 and S40 in CoIE9 being absent in the TA₁₋₁₀₇-ToIB structure.

The ToIB box core of CoIA forms an O ring shape, due to the hydrogen bond between the D11 and the E18 residues, and sits at the bottom of the tunnel in ToIB (Fig. 4B) with six hydrogen bonds stabilizing the interaction with ToIB (Table S1). The ToIB box core region in CoIA provides (i) all the intermolecular hydrogen bonds with ToIB; (ii) seven out of eight intramolecular hydrogen bonds and all the hydrophobic interactions with ToIB, except for one between K9 from CoIA and F219 of ToIB (Tables S2 and S5); and (iii) three out of four watermediated interactions with TolB (Table S3). The additional C-terminal TolB box residues in ColE9, that are not found in ColA, provide an intermolecular hydrogen bond between W46 from ColE9 and L202 of TolB (Table S1); four intramolecular hydrogen bonds between G32 and N44, G36 and S34, G38 and N43, and S37 and S40 (Fig. 4B; Table S5); and hydrophobic interactions between the residues of A33, P45, W46 from ColE9 and P201, M203, F423, Q172, V170 and K422 of TolB respectively (Table S2). These additional contacts presumably explain why ColE9 binds TolB with higher affinity than ColA.

Two calcium ions are required to make the β -propeller tunnel of ToIB electrostatically positive to facilitate binding of the ToIB box of CoIE9, which has a pl value of 3.7 at neutral pH (Loftus *et al.*, 2006). There is only one calcium ion seen in the β -propeller tunnel in the structure of the TA₁₋₁₀₇—ToIB complex, and one sodium ion is far away from the tunnel between the α/β and β -propeller domains (Fig. 3B). Two basic residues K9 and R19 in the ToIB box of CoIA do not form any interactions with ToIB but raise its pl value to 6.1, which could explain why only one calcium ion is required in the β -propeller tunnel of ToIB to facilitate binding of TA₁₋₁₀₇.

ColA does not competitively recruit TolB

It has recently been shown that the binding surfaces of ColE9 and Pal with TolB are identical and that, in the presence of Ca²⁺, the ToIB box of CoIE9 competitively recruits ToIB from Pal, presumably as a means of destabilizing the outer membrane on route to cell killing (Loftus et al., 2006). The K_d value of 1.6 μ M for binding of TA₁₋₁₀₇ to ToIB in the presence of Ca²⁺ is much higher than the value of 90 nM reported for the binding of Pal to TolB in the presence of Ca²⁺ (Loftus et al., 2006), and thus makes it unlikely that the ToIB box of CoIA will competitively recruit ToIB from the ToIB-Pal complex. We confirmed prediction by using analytical gel filtration this chromatography. An interaction was observed between ToIB and TE9_{1-61::DNase} (Fig. 5A), which is a chimeric polypeptide consisting of the first 61 residues of ColE9 fused to the DNase domain (Macdonald et al., 2004), or TA₁₋₁₀₇ (Fig. 5B). However, when the pre-formed TolB–Pal complex was incubated, in the presence of Ca²⁺, with an equivalent concentration of TE9_{1-61::DNase} (Fig. 5C), or TA₁₋ 107 (Fig. 5D), only the ColE9 NDR was able to competitively recruit ToIB as shown by a retention peak (peak 1) that overlapped the retention peak produced by TE91. 61::DNase-TolB, and a retention peak (peak 3) of free Pal (Fig. 5C). As TE9_{1-61::DNase}-ToIB and ToIB-Pal have affinities of binding of 84 nM and 90 nM respectively, in the presence of 1 mM Ca2+ (Bonsor et al., 2007), recruitment of ToIB *in vitro* is incomplete resulting in the presence of residual ToIB–Pal (peak 2) when the ToIB–Pal heterodimer is mixed with TE9_{1-61::DNase} stoichiometrically.

The difference in the ability of CoIE9 and CoIA to competitively recruit ToIB is presumably the result of the seven differences in the amino-acid sequence of their TolB boxes (Fig. 1; Fig. S4). It has been observed that the W46 residue that is unique to CoIE9 becomes buried in a pocket of the ToIB surface and blocks access of Pal to its binding site on ToIB (Bonsor et al., 2007). CoIA does not possess this distal tryptophan residue in its ToIB box (Fig. 1) and there is no occupancy of this surface pocket of ToIB by any residue of the ToIB box of CoIA (Fig. 4B and Fig. S4). To test the importance of the distal tryptophan and other residues of the CoIE9 ToIB box in the competitive recruitment of ToIB, we engineered TA₁₋₁₀₇ by introducing seven mutations K9A, G10S, T13S, R19N, G20N, S21P and G22W to create a mutant of TA₁₋₁₀₇ (YZ67) with a ToIB box that is identical in sequence to that of CoIE9 (Table 2). SPR experiments showed that the K_{d} of the interaction of YZ67 with ToIB was 1.1 µM in the presence of EDTA and 92.1 nM in the presence of Ca²⁺ (Table 2), which are almost identical to the K_{d} values reported for TE9_{pep32-47} binding to ToIB (Loftus et al., 2006). Corrected sensorgrams and residual plots for the YZ67-ToIB interaction are shown in Fig. S1C. We further dissected the role of the seven mutations introduced in YZ67 by engineering TA₁₋₁₀₇ to produce a series of mutant proteins in which a smaller number of the ColA TolB box residues were replaced with the equivalent residues found in the ColE9 TolB box (Table 2). The affinity of binding of the mutant proteins to ToIB correlated well with the number of CoIE9 residues introduced.

To determine whether the increased affinity of the YZ67 mutant protein for ToIB enables competitive recruitment of ToIB from Pal, we used analytical gel filtration chromatography to observe the interaction of YZ67 with TolB in the presence of a stoichiometrically equivalent concentration of Pal, with or without Ca2+. In the absence of Ca2+ the high-molecular-weight retention peak (peak 1a) overlaps the peak produced by the ToIB-Pal interaction (Fig. S5A), whereas with Ca2+ the high-molecular-weight peak (peak 1) shifts to the left superimposing with the peak produced by the interaction of YZ67-ToIB (Fig. S5A). Analysis of these gel filtration traces by SDS-PAGE shows that in the absence of Ca2+, the proteins present in peak 1a are TolB and Pal, and in peak 2a are primarily YZ67 (Fig. S5B). In the presence of Ca2+, the major proteins present in the fractions of peak 1 are ToIB and YZ67 but do contain some Pal, while peak 2 contains mainly low concentrations of all three proteins, and peak 3 contains Pal (Fig. S5B). There is a clear difference in the pattern of proteins in each gel filtration chromatogram that indicates competitive recruitment of ToIB by YZ67 only in the pres-



Fig. 5. ColA binds to TolB but does not competitively recruit TolB from a TolB–Pal complex. A. Analytical gel filtration showing the individual protein peaks attributed to TolB, TE9_{1-61::DNase} and TE9_{1-61::DNase}–TolB complex. B. Analytical gel filtration showing the individual protein peaks attributed to TolB, TA₁₋₁₀₇ and TA₁₋₁₀₇–TolB complex. C. Analytical gel filtration showing the protein peaks attributed to Pal, TE9_{1-61::DNase}, the TolB–Pal and TE9_{1-61::DNase}–TolB complexes, and the peaks produced from a mixture of TolB–Pal incubated stoichiometrically with TE9_{1-61::DNase} that shows the displacement of Pal (peak 3) as TolB is competitively recruited by TE9_{1-61::DNase} (peak 1). Residual TolB–Pal (peak 2) remains due to incomplete recruitment of TolB *in vitro*. D. In contrast when TolB and Pal were mixed together, incubated stoichiometrically with TA₁₋₁₀₇, and run on gel filtration the absence of a protein peak with the same retention time as TA₁₋₁₀₇–TolB demonstrates no competitive recruitment of TolB by TA₁₋₁₀₇. Protein peaks attributed to Pal, TA₁₋₁₀₇, TolB–Pal and TA₁₋₁₀₇–TolB are shown.

ence of Ca²⁺. However, we were aware that the presence of Pal in the SDS-PAGE profile of peak 1 of Fig. S5A is consistent with either a trimeric YZ67–ToIB–Pal complex or two separate heterodimers of ToIB–Pal and YZ67–ToIB running similarly and inseparably through the gel filtration column. To distinguish these two possibilities, we

Table 2. Mutagenesis of the ToIB box of TA₁₋₁₀₇.

Protein	Sequence ^a	K_{d} versus TolB + Ca ²⁻
TA ₁₋₁₀₇	GKGDGTGWSSERGSG	1560 ± 37.7 nM
YZ67	AS S NNPW	92 ± 1.4 nM
YZ66	AS NNPW	$233\pm2.7~\text{nM}$
YZ59	NNPW	298 ± 8.1 nM
TE9 _{pep32-47}	GASDGSGWSSENNPW	84 nM

a. ToIB box sequences of CoIA (TA₁₋₁₀₇) and CoIE9 (TE9_{pep32-47}) are shown along with site-directed mutants of TA₁₋₁₀₇ in which residues of the ToIB box of TA₁₋₁₀₇ were replaced with their equivalent residues from CoIE9.

repeated the gel filtration experiments with ToIB–Pal and YZ78 (a polypeptide that expresses the N-terminal 172 residues $[TA_{1-172}]$ of CoIA with the ToIB box of CoIE9) to allow a greater separation of the YZ78–ToIB and ToIB–Pal dimers. The gel filtration profiles and SDS-PAGE of proteins in each gel filtration peak show the presence of a YZ78–ToIB heterodimer, demonstrating the ability of YZ78 to competitively recruit ToIB from Pal similar to the competitive recruitment seen by the ToIB box peptide of CoIE9 (Fig. 6).

Interestingly, activity assays of full size ColA containing the complete ToIB box of ColE9 (YZ73) demonstrated that the biological activity of YZ73 was reduced by at least 100-fold when compared with ColA (Fig. 7). We therefore introduced the Y58A mutation, which has previously been shown to completely inactivate ColA (Pommier *et al.*, 2005), into the ToIA box of YZ73 and demonstrated that YZ73 containing the Y58A mutation was unable to interact with ToIA by SPR, and was biologically inactive (data not



Fig. 6. Competitive recruitment of ToIB by CoIA containing the ToIB box of CoIE9 (YZ78).

A. Gel filtration of a mixture of ToIB and Pal incubated stoichiometrically with YZ78 in the presence of 1 mM Ca²⁺. Peak 1 of the YZ78–ToIB–Pal mixture superimposes with the YZ78–ToIB control.

B. Fractions collected across peaks 1–4 of the YZ78–TolB–Pal retention profile in A were analysed by SDS-PAGE. Peak 1 contained TolB and YZ78 indicating good separation of YZ78–TolB from any TolB–Pal. Peak 2 is a shoulder peak and contained a mixture of YZ78–TolB and TolB–Pal. Peak 3 contained uncomplexed YZ78, and peak 4 contained free Pal that had been displaced from the TolB–Pal interaction. *Indicates some breakdown product of YZ78 in the uncomplexed fractions.

shown). This confirmed the continued dependence on TolA for the translocation of YZ73 and the deleterious impact on biological activity of a TolB box with higheraffinity TolB binding. Even though YZ73 and ColA share the same number of residues between their respective TolA and TolB boxes, the differences in the nature of their interaction with TolB could result in changes in the relative geometry of their TolB and TolA binding epitopes.

Discussion

Mutational and biophysical studies have indicated that translocation of ColA requires the same set of Tol proteins and outer membrane receptors as the enzymatic E colicins such as ColE9, even though (i) the cytotoxic domains of both types of colicin are different; (ii) translo-

cation to different cellular locations is required for cell killing to occur; (iii) CoIE9, unlike CoIA, binds to sensitive *E. coli* cells as a complex with its immunity protein Im9; and (iv) there is no evidence that CoIE9, unlike CoIA, make any direct interaction with ToIA. From the data presented in this paper we propose that Group A colicins use subtly different mechanisms to recruit the common ToIB portal in order to gain entry into and then kill *E. coli* cells.

The cellular uptake of group A colicins involves the penetration of an NDR of their translocation domains through the cell envelope to make contact with the Tol proteins in the periplasmic space. In the case of CoIE9 this ensures the competitive recruitment of ToIB from the ToIB–Pal complex by the binding of the ToIB box of the colicin (Loftus *et al.*, 2006; Bonsor *et al.*, 2007). The structure of the TA₁₋₁₀₇–ToIB complex reported here shows that the ToIB boxes of CoIE9 and CoIA interact in subtly different ways with the common ToIB translocation portal (Fig. 4B), principally as a result of sequence differences in the distal half of the ToIB box of 0.78 for the TE9₃₂₋₄₇–ToIB complex, 0.70 for the ToIB–Pal complex and 0.66 for the



Fig. 7. ColA expressing the TolB box of ColE9 (YZ73) has at least 100-fold less biological activity than ColA. Cell killing of *E. coli* DH5 α in liquid culture following treatment with 0.1–10 nM of colicin A (A) and 10 nM to 1 μ M of YZ73 (B). An untreated sample was included as a negative control for cell killing of both ColA and YZ73. Comparison of both panels suggests that 0.1 nM and 10 nM ColA had similar killing properties to 10 nM and 1 μ M YZ73 respectively, while 1 nM of ColA had a killing activity similar to 500 nM of YZ73 indicating a reduced activity of YZ73 of, at least, 100-fold when compared with ColA.

TA₁₋₁₀₇-ToIB complex are in good agreement with the relative binding affinities of ToIB for these three ligands and are consistent with the ability of CoIE9, but not CoIA, to recruit ToIB from its complex with Pal. The ability to competitively recruit ToIB was introduced into CoIA when the complete ToIB box of CoIE9 was introduced into the ColA polypeptide, indicating the importance of the second tryptophan residue and the cyclizing hydrogen bond between N44 and G32 in the ColE9 sequence for highaffinity ToIB binding. The role of competitive recruitment of ToIB to the translocation of colicins is, at present, not well established especially allowing for the fact that ToIB has been found as a monomer in the periplasm (Levengood and Webster, 1989) and bound to other outer membrane receptors such as Lpp and OmpA (Rigal et al., 1997; Clavel et al., 1998). TolB has also been shown in vitro to dimerize (Walburger et al., 2002), and forms a weak interaction with TolA (Dubuisson et al., 2002; Walburger et al., 2002; Hands, 2004). Therefore, it is possible that the ColA interacts with ToIB directly in the periplasm or from a lower-affinity complex at the outer membrane.

The lower-affinity interaction of the ToIB box of CoIA with ToIB, as compared with that of CoIE9, may be important for the subsequent interaction of ColA with TolA, which is a component of the Brownian ratcheting process that is proposed to drive the unidirectional translocation of group A colicins (Journet et al., 2001). Our data show that the C-terminus of the ToIB box of CoIA is solvent exposed having no intermolecular interactions with ToIB, which would facilitate an interaction with TolA by residues encompassing Y58-Y90 of the TolA box of ColA (Pommier et al., 2005). A trimeric complex produced by ToIA-ToIB-TA₁₋₁₀₇ was disrupted when the TolB box of ColA (in TA₁₋ 107) was substituted with the ToIB box of CoIE9 (data not shown), suggesting that the higher-affinity complex of TolB with mutated TA_{1-107} (YZ67), mediated by the introduction of the K9A, G10S, T13S, R19N, G20N, S21P and G22W mutations affected the subsequent interaction with ToIA. Indeed we show the importance of ToIA to the activity of YZ73 following the introduction of the TolA box mutation, Y58A, into YZ73 which rendered YZ73 completely inactive.

The role of ToIA in the import of enzymatic E colicins is less clear. It has recently been shown that ToIA along with ToIB are important in harnessing energy from the proton motive force for the release of Im9 from the CoIE9 DNase/ Im9 complex bound to *E. coli* cells (Vankemmelbeke *et al.*, 2009). We assume that energy is not similarly required for the translocation of CoIA as there is no immunity protein bound to the colicin when it is exported from the producing *E. coli* cell (Geli and Lazdunski, 1992).

Making use of the data reported in this paper, we propose subtly different models for the translocation of CoIA and CoIE9. The NDR of CoIE9 contains two separate OmpF binding sites (Housden et al., 2005) and crosses the outer membrane through the lumen of an OmpF monomer (Kurisu et al., 2003: Yamashita et al., 2008). The entry of the ColE9 NDR into the periplasm disrupts the TolB-Pal complex through competitive recruitment of ToIB by the ToIB box. This would then allow ToIB to interact with ToIA leading to the pmf-dependent loss of Im9 from the DNase/ Im9 complex and entry of the DNase domain through a destabilized outer membrane. Delivery of the DNase domain across the inner membrane as an intact molecule. or as a proteolytically cleaved subdomain (de Zamaroczy et al., 2001; Shi et al., 2005) is electrostatically driven and potentially involves the AAA+ ATPase FtsH (Walker et al., 2007). The translocation domain is stalled at this point as no other interactions of physiological significance with ToIA, ToIR or ToIQ occur for enzymatic colicins (Hands et al., 2005; Cascales et al., 2007), and it has not been shown that any residues of the translocation domain distal to the NDR are able to enter the cell envelope of E. coli cells (Zhang et al., 2008). Unlike CoIE9, the NDR of CoIA does not have an OmpF binding motif and does not enter the OmpF lumen (Bainbridge et al., 1998). We suggest that the NDR slides down the side of OmpF (Lazzaroni et al., 2002) to make contact with ToIB thus providing an anchor for a higher-affinity interaction with ToIA. The affinities of CoIA for ToIB and ToIA, respectively, are progressively higher (Hands et al., 2005) providing support for the Brownian Ratcheting hypothesis (Journet et al., 2001). It has also been shown that once bound to ToIA, the CoIA NDR cannot be displaced by TolB even with an excess concentration of the latter (Pommier et al., 2005), but a trimeric complex between all three proteins has been detected in vivo by an antibody overlay experiment (Bouveret et al., 1998) and in vitro by gel filtration chromatography (L. Chan, unpublished). The role of ToIR in the translocation process remains unclear as the affinity of CoIA for ToIR is very low (> 15 µM; Hands, 2004), which suggests that it has no physiological significance, even though a ToIR binding site in ColA has been proposed (Journet et al., 1999; Bouveret et al., 2002).

Support for this model has come from studies on the translocation of colicin N which also slides down the outside of OmpF through an interaction with lipopolysaccharide (Baboolal *et al.*, 2008), and subsequently interacts with TolA, but not TolB, in the periplasm. It is not known why ColA, unlike ColN, interacts with TolB, while both ColA and ColN possess TolA boxes in their NDRs (Raggett *et al.*, 1998; Pommier *et al.*, 2005), a feature that is not present in the NDR of enzymatic colicins. The surprising observation that the translocation domain expressing residues 1–172 of ColA denatures TolAIII on binding (Deprez *et al.*, 2002) is also of significance as it may lead to the destabilization of the cell envelope following the loss of the TolA–Pal transmembrane linkage and

result in entry of the pore forming domain (Cascales *et al.*, 2000).

Our data have shown that the lower affinity of binding and the smaller buried surface area of the ToIB box of CoIA with ToIB are important features in the translocation of CoIA and presumably facilitate the subsequent interaction of the ToIA box of CoIA with ToIA. By mutating the ToIB box residues of CoIA to equivalent residues of CoIE9 we have shown that increasing the affinity of the ToIB box for ToIB has a detrimental effect on the activity of the colicin leading us to predict that Group A enzymatic and poreforming colicins have diverging mechanisms of cellular penetration even though they use a common ToIB portal.

Experimental procedures

Plasmids, bacterial strains, and media

Escherichia coli DH5a was used as the host strain for cloning and mutagenesis. E. coli BL21 (DE3) (Novagen) was used as the host strain for the expression vector pET21a (Novagen). All cultures were routinely grown in Luria-Bertani (LB) broth or on plates of LB agar, supplemented where required with ampicillin (100 µg ml⁻¹). Plasmid pYZ27 contains caa cloned into pET21a via Ndel and Xhol. Plasmid pTA107 was derived from pYZ27 by engineering a stop codon after residue 107 of CoIA. Plasmid pYZ59 was derived from pTA107 by substituting the residues R₁₉GSG₂₂ for N₄₃NPW₄₆ of ColE9; pYZ66 was derived from pYZ59 by substituting the residues K₉G₁₀ with residues A₃₃S₃₄ from ColE9; pYZ67 was derived from pYZ66 by engineering the site directed mutation, T13S; pYZ73 was derived from pYZ67 and contains caa with the CoIE9 ToIB box. Plasmid pRJ379 was used for the production of TolB (Carr et al., 2000), and pSL13 encodes the soluble periplasmic domain of Pal (residues 65-173) with a C-terminal His6-tag (Loftus et al., 2006).

Protein expression and purification

Proteins were overexpressed in BL21 (DE3) cells and purified using nickel affinity chromatography followed by gel filtration chromatography as described previously (Carr *et al.*, 2000; Penfold *et al.*, 2000). Protein nomenclature follows the plasmid designations, such that YZ67 was expressed from pYZ67 and YZ73 was expressed from pYZ73.

Formation of the TA₁₋₁₀₇-TolB complex

TA₁₋₁₀₇ and ToIB, both in 20 mM Tris.CI pH 8.0 and 5 mM CaCl₂, were mixed in equimolar amounts and left at 4°C overnight. The mixed sample was then loaded on a Superdex 75 column (Amersham Biosciences) coupled to an FPLC system (Δ KTA) pre-equilibrated with 20 mM Tris.CI pH 8.0, 5 mM CaCl₂, and run at a flow rate of 0.5 ml min⁻¹. The elution fractions were checked by running 15% SDS-PAGE gels.

Crystallization

The concentration of the sample was checked prior to setting up extensive crystallization screening with the PreCrystallization Test kit (Hampton Research) to determine the most appropriate protein concentration for crystallization trials. Three different concentrations were tested: 5, 10 and 15 mg ml⁻¹, and the best results were obtained at 5 mg ml⁻¹, which was then used for crystallization. The Hydra II microdispensing system (Robbins Hydra, Matrix Technologies Ltd, Wilmslow, England) was used in the initial high-throughput crystallization and screening process. The sparse-matrix factorial search method (Jancarik and Kim, 1991) was used for the screening of initial crystallization conditions, eventually extending the trials to all the following 12 screens (Nextal Biotechnology/Qiagen): Classics, MbClassics, PFGs Anions, Cations, AmSO₄, pH clear, MPD, JCSG+, PACT, PACTpremier, Protein Complexes. The sitting-drop vapourdiffusion method was employed and 96-well crystallization plates (Grenier, Molecular Dimensions) were used, equal volumes of protein and reservoir solution (1 ul each) were dispensed and combined into sitting drops. The plates were sealed tightly with clear tape and kept in an incubator at 20°C. Optimized crystals of the TA₁₋₁₀₇-ToIB complex were obtained at 20°C with 2 μ l of the complex at 5 mg ml⁻¹ in 20 mM Tris-HCl pH 8.0, 5 mM CaCl₂ mixed in equal volumes with reservoir solution containing 20% PEG 10000, 0.1 M Hepes pH 7.5. The crystals grew after 3-4 weeks. Before flashfreezing in liquid nitrogen, crystals were briefly soaked in 22% PEG 10000, 0.1 M Hepes pH 7.5 and 20% glycerol for cryoprotection.

Data collection and phasing

Diffraction data were collected at -180° C on a Rigaku R-AXIS IV⁺⁺ detector using CuK α radiation from a Rigaku Micromax-007 rotating anode, equipped with Osmic VariMax HF optics and an X-stream 2000 cryocooling vapour jet. Data were indexed, integrated and scaled with the programs MOSFLM (Leslie, 1992) and SCALA (Evans, 1997) of the CCP4 (1994) suite. Crystals of the TA₁₋₁₀₇–ToIB complex belong to the monoclinic space group P1211 and contained one molecule in the asymmetric unit with a solvent content of 27.7%. Phases were determined by the molecular replacement method using the program Phaser (McCoy *et al.*, 2005) in the CCP4 suite and the *E. coli* ToIB structure with PDB entry 1C5K (Carr *et al.*, 2000) was used as a search model, after all waters were removed from this file and B factors reset to 20 Å².

Model building and refinement

The model was built manually using COOT (Emsley and Cowtan, 2004) and then refined against the X-ray data to 2.6 Å resolution spacing using restrained and TLS refinement in REFMAC5 (Murshudov *et al.*, 1997). The optimal number of TLS groups, 7, was determined using the TLSMD server (Painter and Merritt, 2006). The final model consists of ToIB, with resolved residues from 33 to 431, and TA₁₋₁₀₇, with resolved residues from 9 to 20; it has excellent geometry and no Ramachandran outliers. Data processing and model refinement statistics are summarized in Table 1. Surface area accessibility calculations were carried out using the program AREAIMOL (Lee and Richards, 1971). All structural figures

were prepared using PYMOL (Delano Scientific). Attempts to collect higher-resolution synchrotron data were not successful.

Colicin activity assay

Liquid growth and spot test assays of biological activity of CoIA and CoIA mutants were conducted as described previously (Hands *et al.*, 2005).

Surface plasmon resonance

Surface plasmon resonance was conducted using a BIAcore X instrument from BIAcore AB (Uppsala, Sweden), operating BIAcore control software. ToIB was immobilized to the matrix of a newly docked CM5 sensor chip, pre-equilibrated in HBS-EP [10 mM Hepes (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) P20 surfactant] running buffer (BIAcore AB), via amine coupling. To determine the R_{max} values of each analyte binding to the ligand, 50 nM ToIB was injected across flow cell 2 of a CM5 chip previously activated with a mixture of 0.1 M ethyl-N-(3-diethylaminopropyl)carbodiimide (EDC, BIAcore AB) and 0.4 M N-hydroxysuccinimide (NHS, BIAcore AB) at a flow rate of 10 µl min⁻¹ and a contact time of 3 min to produce an immobilization of 2100 response units (RU). Two minute injections of up to 20 µM CoIA and ToIB box mutants of CoIA were then performed across the immobilized ToIB at a flow rate of 30 µl min⁻¹. After each analyte injection, the sensor chip surface was regenerated using a 2 min pulse of 10 mM glycine, pH 1.8. Each analyte/ligand interaction was repeated three times and the R_{max} values were determined in HBS-EP buffer and HBS-P, 1 mM CaCl₂, using BIAevaluation software 3.1 to align all the binding curves.

To determine the binding affinity data, the R_{max} of SPR should not exceed 500 RU. Therefore, binding affinity data of each analyte to ToIB was performed across a new ToIB immobilized CM5 chip containing 420 RU of immobilized ToIB using a range of analyte concentrations above and below the expected K_d of the interaction. Global analysis using BIA evaluation software 3.1 was used to fit corrected SPR responses to the theoretical 1:1 Langmuir binding model. Steady-state affinity data for corrected sensorgrams was also evaluated using the general fitting model of the BIAcore 3.1 software. The average equilibrium binding response (Req) for each sensorgram was calculated 50-100 s after injection, plotted against analyte concentration and fitted using the steady state affinity model (Biacore 3.1 software). The affinity data of TA₁₋₁₀₇, YZ67 and TA₁₋₁₀₇ inactive mutants were determined three times in HBS-P buffer containing 1 mM CaCl₂.

Analytical gel filtration

Protein samples were mixed and incubated overnight at 4°C. A Superdex 75 10/300 GL column was equilibrated with two column volumes (24 ml) of 50 mM Tris.Cl, pH 8 containing 0.15 M NaCl and 1 mM CaCl₂ (or 3 mM EDTA) at a flow rate of 0.5 ml min⁻¹. Proteins (30 μ M in 100 μ I) were loaded onto the column at a flow rate of 0.5 ml min⁻¹ and collected as 500 μ I fractions following changes in absorbance of the eluate at A_{280nm} with time. All fractions were analysed on SDS-PAGE.

PDB deposition

Coordinates have been deposited in the Protein Data Bank (PDB ID Code, 3IAX).

Acknowledgements

We thank Colin Kleanthous for kindly providing plasmid pSL13 and Amelia Bostock for engineering the R19A mutation of ColA. Stephan Heeb is acknowledged for assistance with the figures. This work was funded by the BBSRC (grant number, BB/D016320/1) and The Wellcome Trust (grant number, 066850/C/02/A).

References

- Abergel, C., Bouveret, E., Claverie, J.-M., Brown, K., Rigal, A., Lazdunski, C., and Bénédetti, H. (1999) Structure of the *Escherichia coli* TolB protein determined by MAD methods at 1.95 Å resolution. *Structure* 7: 1291–1300.
- Baboolal, T.G., Conroy, M.J., Gill, K., Ridley, H., Visudtiphole, V., Bullough, P.A., and Lakey, J.H. (2008) Colicin N binds to the periphery of Its receptor and translocator, outer membrane protein F. *Structure* 16: 371–379.
- Bainbridge, G., Armstrong, G.A., Dover, L.G., Whelan, K.F., and Lakey, J.H. (1998) Displacement of OmpF loop 3 is not required for the membrane translocation of colicins N and A *in vivo. FEBS Lett* **432**: 117–122.
- Bénédetti, H., Lazdunski, C., and Lloubès, R. (1991) Protein import into *Escherichia coli*: colicins A and E1 interact with a component of their translocation system. *EMBO J* 10: 1989–1995.
- Bonsor, D.A., Grishkovskaya, I., Dodson, E.J., and Kleanthous, C. (2007) Molecular mimicry enables competitive recruitment by a natively disordered protein. *J Am Chem Soc* 129: 4800–4807.
- Boon, T. (1971) Inactivation of ribosomes *in vitro* by colicin E3. *Proc Natl Acad Sci USA* **68:** 2421–2425.
- Bouveret, E., Derouiche, R., Rigal, A., Lloubès, R., Lazdunski, C., and Bénédetti, H. (1995) Peptidoglycan-associated lipoprotein–ToIB interaction. A possible key to explaining the formation of contact sites between the inner and outer membranes of *Escherichia coli. J Biol Chem* **270**: 11071– 11077.
- Bouveret, E., Rigal, A., Lazdunski, C., and Bénédetti, H. (1997) The N-terminal domain of colicin E3 interacts with ToIB which is involved in the colicin translocation step. *Mol Microbiol* **23**: 909–920.
- Bouveret, E., Rigal, A., Lazdunski, C., and Bénédetti, H. (1998) Distinct regions of the colicin A translocation domain are involved in the interaction with ToIA and ToIB proteins upon import into *Escherichia coli. Mol Microbiol* 27: 143– 157.
- Bouveret, E., Journet, L., Walburger, A., Cascales, E., Bénédetti, H., and Lloubès, R. (2002) Analysis of the *Escherichia coli* Tol-Pal and TonB systems by periplasmic production of Tol, TonB, colicin, or phage capsid soluble domains. *Biochimie* 84: 413–421.
- Bowe, F., Lipps, C.J., Tsolis, R.M., Groisman, E., Heffron, F., and Kusters, J.G. (1998) At least four percent of the *Sal*-

© 2009 The Authors

monella typhimurium genome is required for fatal infection of mice. *Infect Immun* **66:** 3372–3377.

- Carr, S., Penfold, C.N., Bamford, V., James, R., and Hemmings, A.M. (2000) The structure of ToIB, an essential component of the *tol*-dependent translocation system, and its protein–protein interaction with the translocation domain of colicin E9. *Structure* **8**: 57–66.
- Cascales, E., Gavioli, M., Sturgis, J.N., and Lloubès, R. (2000) Proton motive force drives the interaction of the inner membrane ToIA and outer membrane Pal proteins in *Escherichia coli. Mol Microbiol* **38**: 904–915.
- Cascales, E., Lloubès, R., and Sturgis, J.N. (2001) The TolQ-ToIR proteins energize ToIA and share homologies with the flagellar motor proteins MotA-MotB. *Mol Microbiol* **42:** 795– 807.
- Cascales, E., Bernadac, A., Gavioli, M., Lazzaroni, J.C., and Lloubès, R. (2002) Pal lipoprotein of *Escherichia coli* plays a major role in outer membrane integrity. *J Bacteriol* **184**: 754–759.
- Cascales, E., Buchanan, S.K., Duche, D., Kleanthous, C., Lloubès, R., Postle, K., *et al.* (2007) Colicin biology. *Microbiol Mol Biol Rev* **71**: 158–229.
- CCP4. (1994) The CCP4 suite: programs for protein crystallography. *Acta Cryst* **D50**: 760–763.
- Clavel, T., Germon, P., Vianney, A., Portalier, R., and Lazzaroni, J.C. (1998) TolB protein of *Escherichia coli* K-12 interacts with the outer membrane peptidoglycanassociated proteins Pal, Lpp and OmpA. *Mol Microbiol* 29: 359–367.
- Collins, E.S., Whittaker, S.B., Tozawa, K., MacDonald, C., Boetzel, R., Penfold, C.N., *et al.* (2002) Structural dynamics of the membrane translocation domain of colicin E9 and its interaction with ToIB. *J Mol Biol* **318:** 787–804.
- Deprez, C., Blanchard, L., Guerlesquin, F., Gavioli, M., Simorre, J.P., Lazdunski, C., *et al.* (2002) Macromolecular import into *Escherichia coli*: the ToIA C-terminal domain changes conformation when interacting with the colicin A toxin. *Biochemistry* **41**: 2589–2598.
- Dubuisson, J.F., Vianney, A., and Lazzaroni, J.C. (2002) Mutational analysis of the ToIA C-terminal domain of *Escherichia coli* and genetic evidence for an interaction between ToIA and ToIB. *J Bacteriol* **184:** 4620–4625.
- Dyson, H.J., and Wright, P.E. (2005) Intrinsically unstructured proteins and their functions. *Nature* **6:** 197–208.
- Elkins, P., Bunker, A., Cramer, W.A., and Stauffacher, C.V. (1997) A mechanism for toxin insertion into membranes is suggested by the crystal structure of the channel-forming domain of colicin E1. *Structure* **5**: 443–458.
- Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Cryst* **D60**: 2126–2132.
- Evans, P. (1997) Joint CCP4 and ESF-EACMB. *Newsletter Protein Crystallogr* **33**: 22–24.
- Garinot-Schneider, C., Penfold, C.N., Moore, G.R., Kleanthous, C., and James, R. (1997) Identification of residues in the putative ToIA box which are essential for the toxicity of the endonuclease toxin colicin E9. *Microbiology* **143**: 2931–2938.
- Geli, V., and Lazdunski (1992) Immunity protein to pore forming colicins. In *Bacteriocins, Microcins and Lantibiotics*. Nato ASI series. James, R., Lazdunski, C., and Pattus, F. (eds). Berlin: Springer Verlag, pp. 171–179.

- Gerding, M.A., Ogata, Y., Pecora, N.D., Niki, H., and de Boer, P.A.J. (2007) The trans-envelope Tol-Pal complex is part of the cell division machinery and required for proper outermembrane invagination during cell constriction in *E. coli. Mol Microbiol* **63**: 1008–1025.
- Germon, P., Ray, M.-C., Vianney, A., and Lazzaroni, J.C. (2001) Energy-dependent conformational change in the ToIA protein of *Escherichia coli* involves its N-terminal domain, ToIQ, and ToIR. *J Bacteriol* **183**: 4110–4114.
- Goemaere, E.L., Cascales, E., and Lloubès, R. (2007) Mutational analyses define helix organization and key residues of a bacterial membrane energy-transducing complex. *J Mol Biol* **366:** 1424–1436.
- Gunasekaran, K., Tsai, C.J., Kumar, S., Zanuy, D., and Nussinov, R.X. (2003) Extended disordered proteins: targeting function with less scaffold. *Trends Biochem Sci* 28: 81–85.
- Hands, S.L. (2004) Biophysical investigations of the mechanism of colicin translocation. PhD Thesis, University of Nottingham, Nottinghamshire, UK.
- Hands, S.L., Holland, L.E., Vankemmelbeke, M., Fraser, L., Macdonald, C.J., Moore, G.R., *et al.* (2005) Interactions of ToIB with the translocation domain of colicin E9 require an extended ToIB Box. *J Bacteriol* **187**: 6733–6741.
- Housden, N.G., Loftus, S.R., Moore, G.R., James, R., and Kleanthous, C. (2005) Cell entry mechanism of enzymatic bacterial colicins: porin recruitment and the thermodynamics of receptor binding. *Proc Natl Acad Sci USA* **102**: 13849–13854.
- James, R., Kleanthous, C., and Moore, G.R. (1996) The biology of E colicins: paradigms and paradoxes. *Microbiology* **142**: 1569–1580.
- James, R., Penfold, C.N., Moore, G.R., and Kleanthous, C. (2002) Killing of *E. coli* cells by E group nuclease colicins. *Biochimie* **84:** 381–389.
- Jancarik, J., and Kim, S.-H. (1991) Sparse matrix sampling: a screening method for crystallization of proteins. *J Appl Cryst* **24**: 409–411.
- Journet, L., Rigal, A., Lazdunski, C., and Bénédetti, H. (1999) Role of ToIR N-terminal, central, and C-terminal domains in dimerization and interaction with ToIA and ToIQ. *J Bacteriol* **181:** 4476–4484.
- Journet, L., Bouveret, E., Rigal, A., Lloubès, R., Lazdunski, C., and Bénédetti, H. (2001) Import of colicins across the outer membrane of *Escherichia coli* involves multiple protein interactions in the periplasm. *Mol Microbiol* **42**: 331–344.
- Kleanthous, C., Kûhlmann, U.C., Pommer, A.J., Ferguson, N., Radford, S.E., Moore, G.R., James, R., and Hemmings, A.M. (1999) Structural and mechanistic basis of immunity towards endonuclease colicins. *Nat Struct Biol* 6: 243–252.
- Kurisu, G., Zakharov, S.D., Zhalnina, M.V., Bano, S., Eroukova, V.Y., Rokitskaya, T.I., *et al.* (2003) The structure of BtuB with bound colicin E3 R-domain implies a translocon. *Nat Struct Biol* **10**: 948–954.
- Lazzaroni, J.C., Dubuisson, J.F., and Vianney, A. (2002) The Tol proteins of *Escherichia coli* and their involvement in the translocation of group A colicins. *Biochimie* **84**: 391–397.
- Lee, B., and Richards, F.M. (1971) The interpretation of protein structures: estimation of static accessibility. *J Mol Biol* **55:** 379–380.

636 Y. Zhang et al.

- Leslie, A.G.W. (1992) Recent changes to the MOSFLM package for processing film and image plate data. In *Joint CCP4 and ESF-EACMB Newsletter on Protein Crystallography*, No. 26. Wolf, W.M., and Wilson, K.S. (eds). Warrington, UK: Daresbury Laboratory.
- Levengood, S.K., and Webster, R.E. (1989) Nucleotide sequences of the *tolA* and *tolB* genes and localization of their products, components of a multistep translocation system in *Escherichia coli. J Bacteriol* **171:** 6600–6609.
- Lloubès, R., Cascales, E., Walburger, A., Bouveret, E., Lazdunski, C., Bernadac, A., and Journet, L. (2001) The Tol-Pal proteins of the *Escherichia coli* cell envelope: an energized system required for outer membrane integrity? *Res Microbiol* **152**: 523–529.
- Loftus, S.R., Walker, D., Mate, M.J., Bonsor, D.A., James, R., Moore, G.R., and Kleanthous, C. (2006) Competitive recruitment of the periplasmic translocation portal ToIB by a natively disordered domain of colicin E9. *Proc Natl Acad Sci USA* **103**: 12353–12358.
- McCoy, A.J., Grosse-Kunstleve, R.W., Storoni, L.C., and Read, R.J. (2005) Likelihood-enhanced fast translation functions. *Acta Cryst* **D61**: 458–464.
- Macdonald, C.J., Tozawa, K., Collins, E.S., Penfold, C.N., James, R., Kleanthous, C., *et al.* (2004) Characterisation of a mobile protein-binding epitope in the translocation domain of colicin E9. *J Biomol NMR* **30**: 81–96.
- Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. *Acta Cryst* **D53**: 240–255.
- Ogawa, T., Tomita, K., Ueda, T., Watanabe, K., Uozumi, T., and Masaki, H. (1999) A cytotoxic ribonuclease targeting specific transfer RNA anticodons. *Science* **283**: 2097– 2100.
- Painter, J., and Merritt, E.A. (2006) TLSMD web server for the generation of multi-group TLS models. J Appl Cryst 39: 109–111.
- Penfold, C.N., Garinot-Schneider, C., Hemmings, A.M., Moore, G.R., Kleanthous, C., and James, R. (2000) A 76-residue polypeptide of colicin E9 confers receptor specificity and inhibits the growth of vitamin B₁₂-dependent *Escherichia coli* 113/3 cells. *Mol Microbiol* **38:** 639–649.
- Pommier, S., Gavioli, M., Cascales, E., and Lloubès, R. (2005) Tol-dependent macromolecule import through the *Escherichia coli* cell envelope requires the presence of an exposed TolA binding motif. *J Bacteriol* **187**: 7526–7534.
- Raggett, E.M., Bainbridge, G., Evans, L.J., Cooper, A., and Lakey, J.H. (1998) Discovery of critical Tol A-binding residues in the bactericidal toxin colicin N: a biophysical approach. *Mol Microbiol* **28**: 1335–1343.
- Rigal, A., Bouveret, E., Lloubès, R., Lazdunski, C., and Bénédetti, H. (1997) The ToIB protein interacts with the porins of *Escherichia coli. J Bacteriol* **179**: 7274–7279.
- Romero, P., Obradovic, Z., Kissinger, C.R., Villafranca, J.E., and Dunker, A.K. (1997) Identifying disordered regions in proteins from amino acid sequences. *Proc IEEE Intl Conf Neural Networks* 1: 90–95.
- Senior, B.W., and Holland, I.B. (1971) Effect of colicin E3 upon the 30S ribosomal subunit of *Escherichia coli. Proc Natl Acad Sci USA* **68:** 959–963.

- Shi, Z., Chak, K.-F., and Yuan, H.S. (2005) Identification of an Essential Cleavage Site in CoIE7 Required for Import and Killing of Cells. *J Biol Chem* **280:** 24663–24668.
- Tozawa, K., MacDonald, C.J., Penfold, C.N., James, R., Kleanthous, C., Clayden, N.J., and Moore, G.R. (2005) Order in an intrinsically disordered protein: the ToIB binding region of colicin E9. *Biochemistry* **44**: 11496–11507.
- Vankemmelbeke, M., Zhang, Y., Moore, G.R., Kleanthous, C., Penfold, C.N., and James, R. (2009) Energy dependent immunity protein release during tol-dependent nuclease colicin translocation. *J Biol Chem* 284: 18932–18941.
- Walburger, A., Lazdunski, C., and Corda, Y. (2002) The Tol/ Pal system function requires an interaction between the C-terminal domain of TolA and the N-terminal domain of TolB. *Mol Microbiol* **44:** 695–708.
- Walker, D.C., Georgiou, T., Pommer, A.J., Walker, D., Moore, G.R., Kleanthous, C., and James, R. (2002) Mutagenic scan of the H-N-H motif of colicin E9: implications for the mechanistic enzymology of colicins, homing enzymes and apoptotic endonucleases. *Nucleic Acids Res* **30**: 3225– 3234.
- Walker, D., Mosbahi, K., Vankemmelbeke, M., James, R., and Kleanthous, C. (2007) The role of electrostatics in colicin nuclease domain translocation into bacterial cells. *J Biol Chem* 282: 31389–31397.
- Ward, J.J., Sodhi, J.S., McGuffin, L.J., Buxton, B.F., and Jones, D.T. (2004) Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. *J Mol Biol* 337: 635–645.
- Wright, P.E., and Dyson, H.J. (1999) Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol 293: 321–331.
- Yamashita, E., Zhalnina, M.V., Zakharov, S.D., Sharma, O., and Cramer, W.A. (2008) Crystal structures of the OmpF porin: function in a colicin translocon. *EMBO J* 27: 2171– 2180.
- Zakharov, S.D., Eroukova, V.Y., Rokitskaya, T.I., Zhalnina, M.V., Sharma, O., Loll, P.J., *et al.* (2004) Colicin occlusion of OmpF and ToIC channels: outer membrane translocons for colicin import. *Biophys J* 87: 3901–3911.
- de Zamaroczy, M., Mora, L., Lecuyer, A., Geli, V., and Buckingham, R.H. (2001) Cleavage of colicin D is necessary for cell killing and requires the inner membrane peptidase LepB. *Mol Cell* 8: 159–168.
- Zhang, Y., Vankemmelbeke, M.N., Holland, L.E., Walker, D.C., James, R., and Penfold, C.N. (2008) Investigating early events in receptor binding and translocation of colicin E9 using synchronized cell killing and proteolytic cleavage. *J Bacteriol* **190**: 4342–4350.

Supporting information

Additional supporting information may be found in the online version of this article.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.